OBJECTIVES: This paper presents the results of an economic evaluation in conjunction with a randomized controlled trial to evaluate the cost-effectiveness of manual therapy, physical therapy and GP care for patients with
Ͻ12 months). RESULTS: Patients mean ϩ SD age was 55 ϩ 15 years and 77% were female. Mean ϩ SD MAF score was 23.3 ϩ 12.3 with a normal range of 1(no fatigue)-50(fatigue). Mean FACIT-F score was 33.2 ϩ 9.3 with a normal range of 52 (no fatigue)-0 (fatigue). The aggregate scores for each instrument were highly correlated with a Pearson's coefficient of Ϫ0.81 (p Ͻ 0.001). CONCLUSION: Based on this analysis, it appears that the FACIT-F has validity for use in the early RA population. However, as follow-up assessments are completed, a more detailed analysis may reveal additional psychometric properties of the instrument in the early RA population and with disease progression. 
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A REVIEW OF FUNCTIONAL STATUS MEASURES FOR WORKERS WITH UPPER EXTREMITY DISORDERS
OBJECTIVE:
The aim of this study was to determine the cost-effectiveness of Acetylcysteïne and DMSO in the treatment of patients with reflex sympathic dystrophy (RSD). METHODS: The study was a prospective, double-dummy, double blind, controlled trial. Patients were followed for one year. The primary outcome measure was the Impairment-level Sum Score (ISS). Cost data were prospectively collected using cost-diaries. Utilities were determined using the EuroQol. Both cost-effectiveness and cost-utility analyses were performed. Differences in mean direct, indirect and total costs between groups were estimated with corresponding 95% Confidence Intervals (CI). Also cost-effectiveness and cost-utility ratios with corresponding 95% CI were calculated using bootstrapping techniques. RESULTS: There was a statistically significant difference in effect (ISS). DMSO generated more reduction than Acetylcysteïne (diff: 1.82 CI:Ϫ4.90;Ϫ1.27). This significant difference appeared also in the subgroup of patients with warm RSD. The total costs were statistically significant lower in the DMSO compared to the Acetylcysteïne group (diff: 2866 CI: 666;5179). This significant difference was also found in the subgroup of patients with warm RSD. The cost-effectiveness and cost-utility ratios showed that DMSO is dominant over Acetylcysteïne. CONCLUSION: In general, DMSO is the preferred method of treatment for patients with RSD. There are some indications that Acetylcisteïne may be more cost-effective for cold RSD, but this was found in a small subgroup only and should be confirmed in a larger trial.
